Related Experiment Video
Updated: May 10, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
Haval Shirwan1, Rajesh K Sharma, Abhishek K Srivastava
1Institute for Cellular Therapeutics; Department of Microbiology and Immunology; University of Louisville; Louisville, KY USA ; James Graham Brown Cancer Center; University of Louisville; Louisville, KY USA.
Abstract:
Tumor-associated antigen (TAA) subunit-based vaccines constitute promising tools for the anticancer immunotherapy. Given the weak antigenic nature of most TAAs, however, the efficacy of TAA-based vaccines requires adjuvants exerting potent immunostimulatory functions. Co-stimulatory members of the tumor necrosis factor ligand (TNFL) family may be used in this sense due to their pleiotropic and robust effects on cells of innate, adaptive and regulatory immune responses.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
The Tumor Microenvironment

